Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first"

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. A, 2000, Pages

  Kereiakes, Dean J ^a   Fry, Edward ^b   Matthai, William ^c   Niederman, Alan ^d   Barr, Lawrence ^e   Brodie, Bruce ^f   Zidar, James ^g   Casale, Paul ^h   Christy, George ⁱ   Moliterno, David ^j   Lengerich, Rose ^a   Broderick, Thomas ^k   Shimshak, Thomas ^a   Cohen, Marc ^l  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^d Greater Ft Lauderdale Heart Group Research   (United States)

^e Midwest Heart Research Foundation   (United States)

^f LeBauer Cardiovascular Research Foundation   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h Lancaster Heart Foundation   (United States)

ⁱ Clinical Investigation Specialists   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k Ohio Heart and Vascular Center   (United States)

^l HAHNEMANN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

Activated clotting time; Platelet glycoprotein IIb IIIa blockade; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MALE; METHODOLOGY; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 18744418112     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ryan TJ, Bauman WB, Kennedy JW, et al. ACC/AHA task force report: Guidelines for percutaneous transluminal coronary angioplasty. A report of the ACC/AHA task force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1993;22;2033-2054.
2. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
3. Ferguson JJ, Dohmen P, Wilson JM, et al. Results of a national survey on anticoagulation for PTCA. J Invas Cardiol 1995;7:136-141.
4. Narins CR, Hillegass WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
5. Hillegass WB, Narins CR, Brott BC, et al. Activated clotting time predicts bleeding complications from angioplasty (Abstr). J Am Coll Cardiol 1994;23:184A.
6. Miller J, Granger C, Bovill E, et al. Rebound increase in thrombin activity after cessation of intravenous heparin (Abstr). Circulation 1993;88:I-202.
7. Smith AJ, Holt RE, Fitzpatrick JB, et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 1996;131:434-439.
8. Matthai WH, Kurnik PB, Groh WC, et al. Antithrombin activity during the period of coronary revascularization: Relation to heparin use, thrombotic complications and restenosis. J Am Coll Cardiol 1999;33:1248-1256.
9. Knight CJ, Panesar M, Wilson DJ, et al. Increased platelet responsiveness following coronary stenting: Heparin as a possible aetioIogical factor in stent thrombosis. Eur Heart J 1998;19:1239-1248.
10. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
11. Granger CB, Hirsh J, Califf RM, et al. for the GUSTO-I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I Trial. Circulation 1996;93:870-878.
12. Granger CB, Becker R, Tracy RP, et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I Trial. J Am Coll Cardiol 1998;31:497-505.
13. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276:811-815.
14. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: Diagnosis and management. Rockville, MD. Agency for health care policy and research and the National Heart, Lung and Blood Institute, Public Health Service. U.S. Department of Health and Human Services. 1994; AHCPR Publication No. 94-0602.
15. Cohen M, Demers C, Gurfinkel EP, et al. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
16. Antman EM, McCabe CH, Gurfinkel P, et al. for the TlMI IIB investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction - results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999;100:1593-1601.
17. Antman EM, Cohen M, Radley D, et al. for the TIMI IIB and ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction. TIMI IIB-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
18. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-2835.
19. Rao AK, Pratt C, Berke A, et al. for the TIMI investigators. Thrombolysis in myocardial infarction (TIMI) trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.